Japan Steps Up Try To Regain Leading Role In iPS Research
This article was originally published in PharmAsia News
Japan is making an additional effort to regain its standing as a leader in the study of induced pluripotent stem cells by tying in with foreign institutions. Kyoto University is discussing a possible alliance with Harvard University of the United States for joint iPS study. The school also expects to begin a joint study of diabetic treatment soon with Novocell, a U.S. biotech. The new alliances come on top of a Kyoto U. link with the University of Toronto in Canada last year. Japan has felt a sense of urgency to step up its iPS research after losing the lead in the field to other countries where laboratories reported great strides last year. (Click here for more - a subscription may be required)
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.